Skip to main content
. Author manuscript; available in PMC: 2008 Aug 1.
Published in final edited form as: Neuron. 2008 Jun 12;58(5):681–693. doi: 10.1016/j.neuron.2008.04.010

Figure 7. LXR agonist treatment reduces Aβ levels and ameliorates plaque burden in Tg2576 mice.

Figure 7

(A) Aged Tg2576 mice (12 month-old) or genetically similar controls were treated for 4 months with normal chow or chow containing GW3965 (120 mg/kg, 33 mg/kg/day). Aβ plaque burden was monitored by 6E10 staining in the hippocampus. Plaque number and plaque area were quantified in (B) and (C) respectively (n=5, *P<0.05; **P<0.01). The levels of Aβ40 (D) and Aβ42 (E) were quantified using ELISA (*P<0.05). (F) The levels of full-length APP, C99 C-terminal fragment, total Aβ, ABCA1 and ApoE were monitored by Western analysis. The results were normalized to β-actin (n=5, *P<0.05; **P<0.01). Quantification of the data is shown under the Western blots.